The Lancet· Shaodong Hong, Ting Zhou, Xue Hou, Xiangjiao Meng, Zhihuang Hu, Wei Zheng, Jiuwei Cui, Yongzhong Luo, Lin Wu, Meijuan Huang, Haipeng Xu, Jie Hu, Yanqiu Zhao, Wenxiu Yao, Yonggui Hong, Jun Cai, Yu Zhang, Chunxia Su, Conghua Xie, Ruoyu Wang, Xiang Li, Qiong He, Liang Zhang, Ruiling Ning, Daren Lin, Tongmei Zhang, Tienan Yi, Liqiang Zhong, Siyuan Huang, Hui Zhao, Jian Fang, Qing Bu, Bihui Li, Zhiye Zhang, Meiqi Shi, Jianhua Shi, Zhiping Deng, Yi Zhu, Hai Zhu, Sa Xiao, Lei Yang, Ni Song, Wenfeng Fang, Li Zhang, Yunpeng Yang, PANKU-Lung01 Investigators·· 6 hours agoScore75
[Articles] Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
In brief
The phase 3 PANKU-Lung01 trial showed that izalontamab brengitecan significantly prolonged progression-free survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced non-squamous NSCLC. The study enrolled patients whose disease had progressed after third-generation EGFR TKI treatment; grade 3 or worse treatment-related adverse events were more frequent than with chemotherapy. The authors state that these results provide the first phase 3 evidence for a bispecific antibody-drug conjugate and support izalontamab brengitecan as a potential treatment option in this population.
Source: The Lancet · thelancet.com